Actively Recruiting
Study of Stopping Beta-Blockers to See Effects on Heart Function and Activity in Patients With Heart Failure and Normal Ejection Fraction Aged 50 to 80
Led by UConn Health · Updated on 2025-09-29
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This research aims to evaluate changes in patients with Heart Failure With Preserved Ejection Fraction HFpEF before and after stopping beta-blocker medication. The study focuses on 30 stable HFpEF patients aged 50 to 80 years who are currently taking beta blockers. Its purpose is to observe how stopping beta blockers affects heart function and patient health over a short period. The study involves two visits spaced about four weeks apart. The first visit takes place during a routine clinic appointment, and the second is a research visit where patients complete questionnaires and undergo a limited echocardiogram. The only intervention is the discontinuation of beta blockers, and there is no long-term follow-up beyond the second visit. Participants will be assessed using questionnaires including the KCCQ-23, echocardiography to examine heart mechanics, biomarker tests, and a 6-minute walk test before and after beta-blocker withdrawal. Researchers will monitor changes in these measures to understand the effects of stopping beta blockers. The total participation lasts about four weeks with no extended monitoring afterward.
CONDITIONS
Brief Title
Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction
Research Team
K
Kai Chen, MD,PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
